A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 228
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DLBCLs
Long Form : diffuse large B-cell lymphomas
No. Year Title Co-occurring Abbreviation
2020 Aggressive B-cell lymphomas with a primary bone marrow presentation. BL, BM, HG-BCLs, TdT
2020 Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. BCR, GC, HSC
2020 Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. HBV, NHL
2020 Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma. CR, MSI, OS, PFS
2020 Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma? CCND1, CNS, MCLs
2020 RNAscope dual ISH-IHC technology to study angiogenesis in diffuse large B-cell lymphomas. JAK, STAT
2020 Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. COO, GCs, sc
2020 TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. GC
2020 TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. GC
10  2020 Tumor lysis syndrome as a risk factor for very early mortality in HIV-associated non-Hodgkin's lymphoma: A 10-year single-center experience. BLs, NHL, PCNSLs, PLWHIV, TLS
11  2020 Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: A pilot study using the Ki67 proliferation index as an example. DIA, FLs, HSI, VA, Vis-NIR
12  2019 Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas. CNS, PCNSL
13  2019 Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors. ---
14  2019 Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas. 5hmC, BLs, EBV, LSH
15  2019 Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients. FL, MALT
16  2019 Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. DAAs, DLBCL, HCV, ICT, R-CHOP, SeqC
17  2019 Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. BCR, BRD4, DEL, DHL
18  2019 EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2. 3'UTR, ABCs, BHRF1, COO, GCBs, LMP1, miR, PD-L1
19  2019 GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. cHL, EBV, NLPHL, NS, PMBLs, TCHRBCLs
20  2019 Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. CI, CSF, DC, LYSA, PCNSLs, R/R
21  2019 Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). CR, LOC, LYSA, non-GCB, ORR, OS, PCNSLs, PFS, PR, PVRL, R/R
22  2019 Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. CR, LOC, LYSA, non-GCB, ORR, OS, PCNSLs, PFS, PR, PVRL, R/R
23  2019 LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. DSB, HR, PARP, T-ALL
24  2019 Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors. cHL, LPDs, MTX, MTX-LPDs, Poly-LPD, RH
25  2019 NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. FL, PI3K, TFL
26  2019 Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. GC
27  2019 Physical torment: A predisposition for diffuse B-cell lymphoma. NHLs
28  2019 Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Ig, MYC-R
29  2019 Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. ABC, EFS, GCB, IHC, PHB, PHB1, PHB2
30  2019 The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. FISH, GCB-DLBCLs
31  2019 Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. DSS, MATV, TLG
32  2018 Activated CARD11 accelerates germinal center kinetics, promoting mTORC1 and terminal differentiation. aCARD11, GC
33  2018 De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge. EBV, HHV-8, HIV
34  2018 Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface. BCL6, PPI
35  2018 Double hit and double expressors in lymphoma: Definition and treatment. Bcl-2, BCL6, DEL, DHL
36  2018 Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. AVT, DAAs, DFS, HCV, IPI, NHL, OS
37  2018 Epstein-Barr virus infection in B-cell Non-Hodgkin's Lymphomas of the oral and maxillofacial region: Is there any evidence? BLs, EBV, NHLs
38  2018 Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. ABC, GCB
39  2018 Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. DLBCL-LT, DLBCL-NOS, NFKBIE or REL
40  2018 How Biophysical Forces Regulate Human B Cell Lymphomas. BCRs
41  2018 PCR-based clonality analysis of antigen receptor gene rearrangements in canine cutaneous plasmacytoma. CD3, FR, IgH, MUM1
42  2018 Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases. DES, EN, FISH
43  2018 Some diffuse large B cell lymphomas (DLBCLs) present with clone-dependent TTF-1 positivity. ---
44  2018 [Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases]. FISH, GCB, LBL
45  2017 A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images. F-FDG, MRI, PET, ROC, T/N
46  2017 A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. ABC, Blimp-1
47  2017 Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. FISH, HGBLs
48  2017 CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration. PTLDs
49  2017 Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. ABC, GCB, R-CHOP
50  2017 Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. ABC, GCB
51  2017 Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. BCR, ETC
52  2017 DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. GCB, OS, PFS
53  2017 Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. CagA, HP, p-ERK, p-SHP2
54  2017 Germline mutations predisposing to diffuse large B-cell lymphoma. ---
55  2017 Hematologic Malignancies Discovered on Investigation of Breast Abnormalities. FLs, MZLs
56  2017 LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. BL, LBCL
57  2017 MYC Immunohistochemistry Predicts MYC Rearrangements by FISH. BL, FISH, IHC
58  2017 Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. ---
59  2017 Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. CD68, LT, MDSCs, OT, pcDLBCL, PD-L1
60  2016 An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. AITL, EBV, HRS-L, PTCLs
61  2016 An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. ABC, DOX, GCB
62  2016 CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. ---
63  2016 Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. mRNA
64  2016 Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. ABC, JAKs
65  2016 Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. cHL, PD-1, PDL1
66  2016 FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. BCR, FOXO1, Syk
67  2016 FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. ROS
68  2016 Functional Implications of the spectrum of BCL2 mutations in Lymphoma. FLD
69  2016 Long Non-coding RNA HOTAIR Expression in Diffuse Large B-Cell Lymphoma: In Relation to Polycomb Repressive Complex Pathway Proteins and H3K27 Trimethylation. HOTAIR, PRC2
70  2016 miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. 3'-UTR, BCL6
71  2016 PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas. GCB, NHLs
72  2016 Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. ABC-DLBCLs, BCL6
73  2016 Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. GCB, IHC, LMICs, LST, NHL
74  2016 UCH-L1 in DLBCL: marker or target? ABC-DLBCL, GC, UCH-L1
75  2015 CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. DLBCL-NOS
76  2015 Loss of PRDM11 promotes MYC-driven lymphomagenesis. PRDM
77  2015 MLL/KMT2A translocations in diffuse large B-cell lymphomas. ---
78  2015 MYC in DLBCL: partners matter. MYC-Rs
79  2015 Overexpression of Activation-Induced Cytidine Deaminase in MTX- and Age-Related Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disorders of the Head and Neck. AID, EBV, Egr-1, LMP1, LPDs
80  2015 The expanding spectrum of EBV+ lymphomas. ---
81  2015 The histological classification of diffuse large B-cell lymphomas. ---
82  2014 AIDS-related non-Hodgkin lymphoma: imaging feature analysis of 27 cases and correlation with pathologic findings. HAART, NHL, PCNS
83  2014 An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. OS, PFS, R-CHOP, TAMs
84  2014 Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1 gene rearrangements. MCL
85  2014 Diffuse large B-cell lymphoma of the sinonasal tract: analysis of survival in 852 cases. DSS, SEER
86  2014 Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. ---
87  2014 Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase. BCR, Ig, UTR
88  2014 Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. PELI1, TCR
89  2014 Primary diffuse large B-cell lymphoma in the anterior hard palate: A rare case report with review of literature. NHL
90  2014 Relevance of miR-21 in HIV and non-HIV-related lymphomas. miRNAs, mRNA, UTR, VMP1
91  2014 The truncate mutation of Notch2 enhances cell proliferation through activating the NF-kappaB signal pathway in the diffuse large B-cell lymphomas. PDTC
92  2014 Utility and diagnostic pitfalls of SOX11 monoclonal antibodies in mantle cell lymphoma and other lymphoproliferative disorders. MCL
93  2013 A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. IgH
94  2013 A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. GC
95  2013 Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. beta2m, CHOP, HBsAg, HBV, IPI, LDH, OS
96  2013 Clinical presentation of anaplastic large-cell lymphoma in the central nervous system. ALCL, ALK, CNS, HD-MTX, OS
97  2013 De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression. ---
98  2013 DNA repair genes are selectively mutated in diffuse large B cell lymphomas. NHEJ
99  2013 EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. ABC, GC, GCB
100  2013 Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. CI, OR